Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab and Zimberelimab in Resected NSCLC (ARIAN)
NCT06431633Phase 3Recruiting
- Sponsor
- Fundación GECP
- Start
- Feb 2025
- Primary completion
- Nov 2031
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing ARM 1: Observation, ARM 2: Zimberelimab and ARM 3: Sacituzumab Govitecan + Zimberelimab (3 arms). Primary endpoint: Disease-Free Survival at 36 months. Started Feb 2025; status: recruiting.
02
Drugs
sacituzumab govitecanzimberelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06431633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06431633.